UK: Keep Calm and Carry On … Differently
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Address: Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS, United Kingdom ,United Kingdom
Tel: +44 (0) 1344 424 600
Web: http://www.boehringer-ingelheim.co.uk/
Boehringer Ingelheim is a family owned company whose distinctly independent structure means that we are not constrained by the short-term needs of individual shareholders and can focus on the future with long-term strategies of vision and leadership. Boehringer Ingelheim was founded in 1885 by Albert Boehringer and remains a familyowned company. Today we are the fastest growing company amongst the world’s 15 leading pharmaceutical companies.
Annual sales are €12.7 billion worldwide (2009) and 21% of the net sales from its Prescription Medicine business is invested into research and development. The company now employ more than 41,500 people and is committed to remaining family-owned. Albert’s great grandson, Christian Boehringer, is the Chair of the Shareholders’ Committee which manages 142 affiliated companies in 50 countries around the globe. Our headquarters remain in Ingelheim, near Frankfurt in Germany.
Boehringer Ingelheim’s vision, ‘Value through Innovation’, mirrors the founder’s own belief in the importance of innovative thinking and that, as well as being financially profitable, products should be pioneering and of genuine benefit to patients. This independent status frees the company from stock market expectations, and allows for long-term strategies, rather than short-term priorities.
In the United Kingdom, Boehringer Ingelheim was established in 1962 and is one of the fastest growing pharmaceutical companies in the UK, with total sales of £388 million in 2009 (independent audit). The business focuses on clinical research, data management, sales and marketing.
Boehringer Ingelheim is involved in three key healthcare areas: Prescription Medicines, Over-The-Counter (OTC) products and Animal Health. In each sector, the company has world-class medicines to treat patients.
The company has a reputation for providing effective products for the treatment of chronic obstructive pulmonary disease (COPD), heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson’s disease, arthritis and pain relief in cancer.
These products are supported by a wide range of services, designed to help the medical profession deliver the best possible healthcare to patients.
This underlines Boehringer Ingelheim’s commitment to improving health and quality of life in the UK.
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
The Window Conference Center is hosting at least six pharmaceutical events within a month, and has a broad prior history of orchestrating such occasions. How important is the pharmaceutical industry…
Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why…
You joined Apodi in 2008, after a hiatus from the industry following the sale of your previous company, In2Focus, in 2007. What has been the most challenging aspect of your…
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
See our Cookie Privacy Policy Here
